Physician profile
Brian P Wolfman
NPI 1336309673
$14,797.59
in general payments reported to CMS, 2019-2025
44 companies · $2,759 in 2025
The $2,759 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $928 · 2021: $1,097 · 2022: $1,976 · 2023: $2,582 · 2024: $3,694 · 2025: $2,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,909 · Education: $85.95 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,908.59 |
| Education | $85.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,062.32 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,998.49 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $1,249.67 | 2019-2025 | Livdelzi, Veklury |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $906.17 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Scientific Affairs, LLC | $900.64 | 2019-2024 | Tremfya, Stelara |
| Pfizer INC. | $844.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $620.75 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $603.07 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Celgene Corporation | $520.24 | 2021-2024 | Zeposia |
| Genzyme Corporation | $462.85 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $363.06 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $267.70 | 2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $265.06 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $259.23 | 2019-2024 | Dificid |
| Ardelyx, INC. | $243.80 | 2022-2025 | Ibsrela |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $220.67 | 2019-2024 | Rebyota, Cimzia |
| Shionogi INC | $176.03 | 2019-2024 | Fetroja |
| Evoke Pharma, INC. | $150.87 | 2021-2025 | |
| Daiichi Sankyo INC. | $149.65 | 2020-2024 | Injectafer |
| Novo Nordisk INC | $136.87 | 2023-2025 | Wegovy |
| Madrigal Pharmaceuticals | $136.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Covidien LP | $114.47 | 2019 | |
| Ethicon US, LLC | $112.63 | 2019 | |
| Redhill Biopharma INC. | $110.03 | 2020-2023 | Talicia, Aemcolo |
| Regeneron Healthcare Solutions, INC. | $102.93 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $92.62 | 2019-2021 | |
| Celltrion USA INC. | $87.13 | 2024-2025 | Vegzelma |
| Astellas Pharma US INC | $85.95 | 2023 | |
| Romark Laboratories, Lc | $83.41 | 2020 | |
| Nestle Healthcare Nutrition INC. | $71.90 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $56.62 | 2020-2023 | Ocaliva |
| Vivus LLC | $43.94 | 2019-2020 | |
| Allergan, INC. | $40.90 | 2019 | |
| Qol Medical, LLC | $38.76 | 2019-2023 | Sucraid |
| Braintree Laboratories, INC. | $38.73 | 2019-2023 | Suflave |
| Ipsen Biopharmaceuticals, INC | $36.77 | 2025 | Iqirvo |
| Amgen INC. | $32.91 | 2023 | Amjevita |
| Boston Scientific Corporation | $23.10 | 2019 | |
| Aimmune Therapeutics, INC. | $17.38 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $17.24 | 2023 | Idacio |
| Medtronic USA, INC. | $14.31 | 2019 | |
| Alfasigma USA, INC. | $13.82 | 2020 | |
| Teleflex LLC | $13.20 | 2024 | Solesta |
| Shire North American Group INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wolfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.